Taysha Gene Therapies, Inc. (TSHA) stock
Close on Nov 12, 2026Market cap $1.37BP/E –Yield –
Taysha Gene Therapies, Inc. saw revenue fall 13.1% to $5.49M over the twelve months to Sep 30, 2026. Free cash flow was -$141.66M. At the latest close the market valued the company at $1.37B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.37B
- P/E ratio
- –
- Price to sales
- 250.09
- Price to book
- 3.84
- Dividend yield
- –
- Free cash flow yield
- -10.33%
Fundamentals
- Revenue
- $5.49M
- Net income
- -$156.03M
- EPS, diluted
- -$0.43
- Free cash flow
- -$141.66M
- Book value per share
- $0.88
- Diluted shares
- 406M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $4.28
- Open
- $4.23
- Day's range
- $4.04 – $4.42
- Volume
- 3,880,632
- Average volume (20 days)
- 3,472,169
- Index membership
- Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
- Beta (5 years)
- 2.10
- 52-week range
- $3.46 – $7.30
- RSI (14 days)
- 47.7
- Volatility (1 year)
- 71.0%
- Relative volume
- 1.14×
- WACC
- 15.0%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | TSHA | S&P 500 | Difference | TSHA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +1.7% | -2.7% | +4.4 pts | ||
| 3 months | -34.3% | -1.7% | −32.5 pts | ||
| Year to date | -23.5% | +11.9% | −35.3 pts | ||
| 1 year | -3.4% | +12.0% | −15.4 pts | ||
| 3 years | +179.7% | +78.2% | +101.6 pts | +40.9% | +21.2% |
| 5 years | -71.8% | +73.2% | −145.1 pts | -22.4% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Taysha Gene Therapies filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- News
- Update
- Update
About Taysha Gene Therapies
Biological Products, (No Diagnostic Substances)
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company that develops adeno-associated virus-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical development program is TSHA-102, an investigational gene therapy for the treatment of females with Rett syndrome caused by MECP2 loss-of-function mutations. The company focuses on developing transformative treatments to serve patients suffering from severe monogenic central nervous system disorders and their caregivers.
Company profile, executives and historyTaysha Gene Therapies stock: common questions
What is Taysha Gene Therapies's stock price?
TSHA closed at $4.21 on Nov 12, 2026, down 1.64% on the day. Over the past 52 weeks it traded between $3.46 and $7.30.
What is Taysha Gene Therapies's market cap?
Taysha Gene Therapies was worth $1.37B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is TSHA's P/E ratio?
Taysha Gene Therapies lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.43), so it has no meaningful P/E ratio.
How much revenue does Taysha Gene Therapies make?
Taysha Gene Therapies reported revenue of $5.49M for the twelve months to Sep 30, 2026, down 13.1% from a year earlier.
Does Taysha Gene Therapies pay a dividend?
No. Taysha Gene Therapies has not paid a cash dividend over the last twelve months.
When does Taysha Gene Therapies report earnings next?
Taysha Gene Therapies's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has TSHA stock performed over the past year?
Including dividends, TSHA returned -3.4% over the past year, against +12.0% for the S&P 500.
How many TSHA shares are sold short?
53M shares were sold short at the latest FINRA report, 18.39% of the float, or 14.8 days of average trading volume.
Who are Taysha Gene Therapies's competitors?
Companies most similar to Taysha Gene Therapies by business, industry and size include TCRX, ALGS, CRBU, RLAY, OCGN.
See a number that looks wrong?